Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Neurotherapeutics Network Product Development RFI

by Global Biodefense Staff
March 22, 2013

The Blueprint Neurotherapeutics Network (BPN) through the National Institute of Neurological Disorders and Stroke (NINDS) is considering developing a drug product development program for the manufacture and formulation of dosage forms suitable for administration in preclinical and clinical studies.

The goal of the product development program is to manufacture the active pharmaceutical ingredient (API), formulate the API, package, label, store, and distribute completed drug product to preclinical and clinical trial sites. The NINDS envisions awarding a contract for drug manufacturing and formulation services. The Institute is conducting market research to help determine how best to structure contracts for this work.

The BPN offers neuroscience researchers a “virtual pharma” network of contract service providers and consultants with extensive industry experience to develop promising hit compounds from chemical optimization through Phase I human clinical testing. A long term goal is to produce effective medication for a disorder of the nervous system that is currently poorly treated or untreatable. BPN will provide early chemistry knowledge and assist in technology transfer from discovery labs to the product development service provider. Services described below are important next steps for BPN contributors and quality service facilities are needed to develop and prepare drug products for human testing.

The NINDS is considering a drug product development program to assist our BPN contributors. This program is envisioned as a collaborative effort between a service facility and contributors with compounds ready to manufacture.

The service facility shall provide:

  • • Chemistry scale up and process development
  • • Manufacture of active pharmaceutical ingredients
  • • Receipt and storage of API
  • • Preformulation & Formulation of API
  • • Fill and finish of formulations suitable for clinical trial
  • • Packaging, labeling, and storage
  • • Distribution to clinical trial sites

This Request for Information (RFI) seeks input on the design of this program from potential service contractors with staffing and equipment for drug product development studies and GMP manufacturing through Phase I and/or Phase II clinical trials.

Further details are available under Solicitation Number: NINDS-RFI-NS-13-001. Responses are due by April 22, 2013.

Read more about the network: NIH Blueprint for Neuroscience Research.

Tags: RFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC